Literature DB >> 2477044

Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia.

G Bråne1, C G Gottfries, K Blennow, I Karlsson, A Lekman, L Parnetti, L Svennerholm, A Wallin.   

Abstract

Patients with Alzheimer disease (AD, onset less than 65 years of age, n = 13) and senile dementia of the Alzheimer type (SDAT, onset greater than or equal to 65 years of age, n = 28) were investigated for cerebrospinal fluid (CSF) content of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxy-phenylglycol (MHPG) and compared with a group of controls (n = 26). A geriatric rating scale, the Gottfries-Bråne-Steen scale, was used to assess impairment of motor performance, intellectual and emotional functioning, and symptoms common in dementia disorders. The HVA levels in CSF were significantly lower in the AD group than in the SDAT group and controls. MHPG was slightly but significantly increased in the SDAT group when compared with the controls. The HVA and 5-HIAA concentrations were correlated negatively with impairment of motor performance in the SDAT group; 5-HIAA correlated positively with impaired performance in the AD group; and 5-HIAA/HVA ratios were correlated positively with the performance variables. HVA correlated significantly and negatively with "impaired wakefulness" and "inability to increase tempo" in the SDAT group. 5-HIAA and the ratio 5-HIAA/HVA correlated significantly and positively with some items measuring intellectual and emotional impairment. In the AD group, "anxiety" and "fear-panic" correlated positively with 5-HIAA and "restlessness" with MHPG. The data indicate qualitative differences in the CSF monoamine pattern between AD and SDAT.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477044     DOI: 10.1097/00002093-198903030-00004

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  4 in total

Review 1.  The biological basis of behavioral symptoms in dementia.

Authors:  L Garand; K C Buckwalter; G R Hall
Journal:  Issues Ment Health Nurs       Date:  2000 Jan-Feb       Impact factor: 1.835

2.  Noradrenergic hyperactivity after partial fornix section: role in cholinergic dependent memory performance.

Authors:  S J Sara; C Dyon-Laurent; B Guibert; V Leviel
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

3.  Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms.

Authors:  Heidi I L Jacobs; Joost M Riphagen; Inez H G B Ramakers; Frans R J Verhey
Journal:  Mol Psychiatry       Date:  2019-05-28       Impact factor: 15.992

4.  Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.

Authors:  Tiffany W Chow; Bruce G Pollock; Norton W Milgram
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.